Cafepharma Today

April 25 2018 - Positive results for AbbVie’s rheumatoid med

Positive results for AbbVie’s rheumatoid med
Celldex laying off a quarter of its staff
GSK’s Trelegy Ellipta has new indication in US
Will Pfizer’s Trumenba catch up to GSK’s Besero?
*please scroll down for all the latest news*
*scroll through previous pages at the bottom to get older news*

Today's most popular searches:

For banking news and anonymous forums, be sure to check out cafebanking.com

Current News

submit a press release
After some Thursday drama, Shire weighs Takeda's cash-sweetened $61.5B offer
Fierce Pharma
Monday, April 23, 2018 - 11:07am
tags:
Shire, Takeda, M&A
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
CP Wire
Monday, April 23, 2018 - 11:01am
tags:
Alnylam, EMA, orphan drugs, ALN-TTRsc02, ATTR amyloidosis
A Busy Week for the Supreme Court in FCA Matters
FDA Law Blog
Monday, April 23, 2018 - 9:41am
tags:
FDA, False Claims Act, Gilead Sciences
Sage Postpartum Depression Drug Heads to FDA Review
Xconomy
Monday, April 23, 2018 - 9:35am
tags:
SAGE Therapeutics, FDA, brexanolone, postpartum depression
FDA Fails to Approve Pfizer's Biosimilar of Roche's Herceptin
CP Wire
Monday, April 23, 2018 - 9:28am
tags:
Pfizer, FDA, Roche, Herceptin, biosimilars
Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
Market Realist
Monday, April 23, 2018 - 9:18am
tags:
Merck, relebactam, beta-lactamase inhibitors, clinical trials
FDA Grants Breakthrough Therapy Status to Pfizer's Trumenba for Prevention of Meningococcal B Disease in Children
CP Wire
Monday, April 23, 2018 - 9:15am
tags:
Pfizer, Trumenba, vaccines, meningococcal B, FDA, breakthrough status
Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage
Endpoints
Monday, April 23, 2018 - 9:14am
tags:
Prothena, AL amyloidosis, clinical trials, NEOD001
Pharma sector growth slowing down in US
GoinPharma
Monday, April 23, 2018 - 9:12am
tags:
prescription data, drug spending
Fresenius SE Walks Away from $4.3 Billion Takeover of Akorn
CP Wire
Sunday, April 22, 2018 - 11:18pm
tags:
Fresenius SE, Akorn, M&A

Pages

Latest CP Wire Articles

Is Vaxart One to Watch – Maybe
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
OrphoMed's IBS-D Candidate ORP-101 Receives Fast Track Designation
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
New Data For Alder BioPharmaceuticals' Eptinezumab Shows Long-Term Reduction in Episodic Migraine
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
Interview With Hatch-Waxman Expert Kurt Karst
Overview of Pfizer's Biosimilar Program
FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
GSK's Trelegy Ellipta Gains New Indication in the US for the Treatment of Patients With COPD

Latest Pharmagather Articles

Medical Imaging and Pharma: Bridging the Gap
pharmexec technology
Calculate Your Way Out of Bad Yields
In the Pipeline
Are Online Social Networks the New Corporate Currency?
Digital Pharma Blog
The Fuzzy Free-For-All
In the Pipeline
The Gross-to-Net Bubble Topped $150 Billion in 2017
Drug Channels
BenevolentAI: Worth Two Billion?
In the Pipeline
CBI’s 14th Annual Commercial Contract & Chargeback Excellence
Drug Channels
FDA, Industry Prepare for New User Fee Initiatives
pharmexec r&d
Survival/Success in the Age of Too Much Information
pharmexec marketing
Pharma Jobs from Indeed

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

Pharma and Device News from NASDAQ

NetworkNewsWire Announces Publication on Good News in Biotech Advancements Through Cannabis Delivery Technology
Wednesday, April 25, 2018 - 8:30am
Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update
Wednesday, April 25, 2018 - 8:00am
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors
Wednesday, April 25, 2018 - 7:00am
Sharps Compliance Reports Fiscal 2018 Third Quarter Results
Wednesday, April 25, 2018 - 6:55am
Sunniva Inc. to Delay Earnings Release Until April 30, 2018
Tuesday, April 24, 2018 - 9:39pm
Icon Media Holdings, Inc. Enters Into Joint Services Agreement with DMR Biologics
Tuesday, April 24, 2018 - 10:30am
Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference
Tuesday, April 24, 2018 - 9:27am
Organovo to Present at 2nd Annual NASH Summit
Tuesday, April 24, 2018 - 8:05am
Catalyst Pharmaceuticals Introduces New Corporate Website
Tuesday, April 24, 2018 - 8:03am
Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
Tuesday, April 24, 2018 - 7:30am

Breaking Healthcare News - powered by Seeking Alpha

Premarket analyst action - healthcare
Tuesday, April 24, 2018 - 8:38am
Biogen Q1 revenues up 11%; non-GAAP EPS up 16%; shares off 1% premarket
Tuesday, April 24, 2018 - 8:10am
PAVmed in-licenses device used to detect precursor to esophageal cancer
Tuesday, April 24, 2018 - 8:08am
MEDNAX acquires Houston radiology practice
Tuesday, April 24, 2018 - 7:53am
Sanofi R&D chief to retire in late June
Tuesday, April 24, 2018 - 7:49am
TESARO's niraparib shows treatment effect in late-line ovarian cancer
Tuesday, April 24, 2018 - 7:38am
Eli Lilly Q1 revenues up 9%; non-GAAP EPS up 37%; raises 2018 guidance; shares ahead 3% premarket
Tuesday, April 24, 2018 - 7:24am
Prothena bails on AL amyloidosis candidate NEOD001; shares down 62% premarket
Monday, April 23, 2018 - 8:49am
ARCA Biopharma and Medtronic extend Gencaro clinical trial collaboration agreement
Monday, April 23, 2018 - 8:47am
Henry Schein to spin off and merge its animal health business with Vets First Choice
Monday, April 23, 2018 - 8:41am

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.